Region Midtjylland — Sponsor Intelligence | 59 EU Trials

Filter these 59 trials by condition, phase, country and more.

Open in Search →

59 Registered trials

36 Recruiting

14 Completed trials

4 Countries active

90 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I/II

Phase III/IV

Phase IV

Phase III: 11 Phase II/III: 1 Phase II: 8 Phase I/II: 6 Phase III/IV: 7 Phase IV: 21 Phase I: 2 Phase I (Other): 2 Phase I (FiH): 1

Oversight events:

1 serious breach 1 temporary halt across 2 trials

View oversight register →

100%

14 of 14 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Chronic hepatitis B 2 Turner's syndrome 2 Obesity 1 Implant site infection 1 Non-alcoholic steatohepatitis 1 Glioblastoma multiforme 1 Glioblastoma 1 Malignant glioma 1 Tubulointerstitial nephritis 1 Chronic kidney disease 1 Low anterior resection syndrome 1

Top IMPs

ESTRADIOL 5 SODIUM CHLORIDE 3 FUROSEMIDE 2 IBUPROFEN 2 LIDOCAINE HYDROCHLORIDE 2 PARACETAMOL 2 POMALIDOMIDE 2 PROGESTERONE PH. EUR. 2 SEMAGLUTIDE 2 TAMSULOSIN HYDROCHLORIDE 2 VENETOCLAX 2 ALFACALCIDOL 1

All trials

59 total

Rectally administered micronized progesterone for luteal phase support in hormone replacement therapy frozen embryo transfer (HRT-FET) cycle… Not authorised

2023-504616-15-00 Phase III 1 country ESTRADIOL; PROGESTERONE PH. EUR.
An ascending dose study to determine the safety and effect of antibodies against hepatitis B (The SAMBA Study) Not authorised

2023-508444-22-00 Phase I 2 countries
The effect of suprainguinal fascia iliaca compartment block Not authorised

2023-510388-37-00 Phase II 1 country GADOTERIC ACID; ROPIVACAINE HYDROCHLORIDE; SODIUM CHLORIDE
Medical therapy after shock wave lithotripsy Not authorised

2024-510792-38-00 Phase III 1 country FUROSEMIDE; IBUPROFEN; PARACETAMOL; TAMSULOSIN HYDROCHLORIDE
Medical therapy after shock wave lithotripsy Not authorised

2024-510792-38-01 Phase III 1 country FUROSEMIDE; IBUPROFEN; PARACETAMOL; TAMSULOSIN HYDROCHLORIDE
Allogeneic adipose tissue-derived Mesenchymal stromal cells for the treatment of chronic-active antibody mediated rejection in Kidney transp… Pending

2024-510723-18-00 Phase I (FiH) 1 country ALLOGENEIC ADIPOSE-DERIVED MESENCHYMAL STEM CELLS IN VITRO EXPANDED
Comparison of Desmopressin (Minirin vs. Sandoz) in Children with Bedwetting. Pending

2025-521256-29-00 Phase IV 1 country DESMOPRESSIN; DESMOPRESSIN ACETATE
Continuous versus intermittent intravenous furosemide treatment in patients hospitalised with acute heart failure Pending

2025-523589-26-00 Phase IV 1 country
Impact of treatment with TransCon PTH on Quality of Life, cognitive function, brain structure, and cerebral capillary bloodflow in patients … Pending

2025-523930-14-00 Phase IV 1 country ALFACALCIDOL; PALOPEGTERIPARATIDE
Progesterone supplementation after letrozole-stimulated insemination Pending

2025-524327-53-00 Phase IV 1 country PROGESTERONE
A study to determine the safety and effect of antibodies against hepatitis D (the SAMBA-D study) Recruiting

2025-522125-36-00 Phase I (Other) 2 countries
Daridorexant treatment in adolescents with enuresis. Recruiting

2025-521443-20-00 Phase III 1 country DARIDOREXANT
Testosterone Replacement Therapy in Women with Turner Syndrome Recruiting

2024-517755-12-00 Phase II 1 country TESTOSTERONE
Cabergoline for Episodic Migraine (PROTECT) Recruiting

2025-522323-10-00 Phase III 1 country CABERGOLINE
Impact of Early Thyroid Hormone Replacement on Kidney Function and Health-Related Quality of Life in Patients at Risk of Postoperative Hypot… Recruiting

2025-524175-23-00 Phase IV 1 country
COMPARISON OF ZINC ACETATE DOSE REGIMENS (GALZIN VS. ET-700) FOR THE TREATMENT OF WILSON DISEASE: A PHARMACODYNAMIC 64CUCL2 PET/CT STUDY IN … Recruiting

2025-523372-24-00 Phase II 1 country ZINC
The REVERT-PREDIABETES trial Recruiting

2025-522970-35-00 Phase III/IV 1 country
Early-stage clinical trial investigating the individual and combined effect of two drugs, senicapoc and perampanel, as part of the treatment… Recruiting

2025-522605-37-00 Phase I (Other) 1 country
Inhibiting BCL-2 at the start of HIV treatment to reduce the HIV reservoir in people living with HIV Recruiting

2025-521841-26-00 Phase I/II 2 countries VENETOCLAX
The DALBA-study Introduction of the antibiotic dalbavancin in orthopaedic surgery – an evaluation of: • Health economic costs • Patient-repo… Recruiting

2025-522088-13-00 Phase IV 1 country
Heart rate control: Betablockers or Ivabradine therapy before cardiac computed tomography Recruiting

2025-522741-21-00 Phase IV 1 country
EUROpean pragmatic multicenter randomized trial on platelet inhibition and/or lipid lowering treatment in Covert Brain Infarction (CBI) Recruiting

2025-521452-30-01 Phase III 1 country
Semaglutide and Finerenone for Kidney and Vascular Protection in CKD Recruiting

2025-522503-18-00 Phase IV 1 country FINERENONE; SEMAGLUTIDE
Pomalidomide in people with chronic hepatitis B virus (HBV) infection: Safety and immune-enhancing effects (The PIPPI Study) Recruiting

2025-521030-29-00 Phase I/II 1 country POMALIDOMIDE

Showing 1–24 of 59 trials

← All sponsors A–Z